Table 4.

Patients who had recurrent iMN and received rituximab treatment: Patient characteristics at the time of rituximab administration

VariablePatient 8Patient 9Patient 10Patient 11
Time since renal transplantation20 months20 months36 weeks15.2 years
Time since diagnosis of recurrent MN6 months5 days34 weeks3 weeks
BP (mmHg)130/88150/90130/80130/90
Edema2 to 3+TraceTrace0
Immunosuppressive regimenTacrolimus, MMFTacrolimus, azathioprineTacrolimus MMFCyclosporine, azathioprine, prednisone
ARBLosartanLosartanCandesartan
DiureticsFurosemide
StatinsSimvastatinAtorvastatin
OthersAmlodipine, allopurinol, testosterone, propranolol, gabapentin, epoietin alfaASA, calcium carbonate, labetalolAmlodipine, ASA, nadolol
  • ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; MMF, mycophenolate mofetil.